U.S. markets close in 57 minutes
  • S&P 500

    4,161.48
    -23.99 (-0.57%)
     
  • Dow 30

    34,076.03
    -124.64 (-0.36%)
     
  • Nasdaq

    13,896.07
    -156.27 (-1.11%)
     
  • Russell 2000

    2,229.11
    -33.56 (-1.48%)
     
  • Crude Oil

    63.38
    +0.25 (+0.40%)
     
  • Gold

    1,770.60
    -9.60 (-0.54%)
     
  • Silver

    25.85
    -0.25 (-0.98%)
     
  • EUR/USD

    1.2042
    +0.0062 (+0.52%)
     
  • 10-Yr Bond

    1.6010
    +0.0280 (+1.78%)
     
  • GBP/USD

    1.3989
    +0.0149 (+1.08%)
     
  • USD/JPY

    108.1130
    -0.6700 (-0.62%)
     
  • BTC-USD

    55,636.72
    +401.38 (+0.73%)
     
  • CMC Crypto 200

    1,257.97
    -40.98 (-3.16%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

FDA rejects Pacira's application for expanded use of pain drug

March 2 (Reuters) - The U.S. Food and Drug Administration rejected Pacira Pharmaceuticals Inc's application for expanding the use of its pain drug, exparel.

Exparel is currently used to manage post-surgical pain at the site of an operation and Pacira sought to expand its use as a nerve numbing injection, for cases where it is difficult to inject a painkiller directly into the affected area.

(Reporting by Amrutha Penumudi in Bengaluru; Editing by Savio D'Souza)